Loading...

INSM INSMED INC Operational Disruptions 8-K Filing

NSMD

NSM

INSMED INC

(INSM)

2025 8-K

Positive Study Results

Director Departure

Upcoming Presentation

Clinical Study Results

EU Approval Granted

Financial Results Report

Financial Statements

Equity Offerings

Product Expansion

Debt-Equity Swaps

Financial Statements

Rights Offerings

Debt-Equity Swaps

Management Change

Financial Results

FDA Review Accepted

Investor Conference

Agreement Termination

Loan Agreement Update

Redemption of Notes

Financial Results Press Rel...

Regulation FD Disclosure

Redemption of Convertible S...

Notice from AstraZeneca

Webinar on Market Outlook

Underwriting Agreement

Positive Phase 3 results fo...

Approval of Amendment to In...

Financial Results and Safet...

Sales Agreement and Financi...

Regulation FD Disclosure

Financial Results Press Rel...

Financial Results Press Rel...

Annual Meeting and Approval...

Earnings Reports

Earnings Reports

Regulation FD Disclosure

External Links:

On December 17, 2025, Insmed Inc. announced results from a study on their drug brensocatib for treating chronic rhinosinusitis, revealing efficacy differences compared to placebo. Additionally, they acquired INS1148, a monoclonal antibody for respiratory diseases.

AI Assistant

INSMED INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.